Dr. Michael T. Lyster, MD

Dr. Lyster practices at Havasu Regional Medical Center in Lake Havasu City, Arizona, part of Lifepoint Health.

Dr. Lyster's NPI, 1114916350, was assigned on October 20, 2005. Dr. Lyster holds Arizona license 42959.

Dr. Lyster's primary practice is Havasu Regional Medical Center, at 101 Civic Center Lane, Lake Havasu City, AZ 86403 in Mohave County. The practice phone is (928) 855-8185.

Dr. Lyster's primary practice is Havasu Regional Medical Center in Lake Havasu City, Arizona, part of Lifepoint Health. Dr. Lyster is also affiliated with Onvida Health Yuma Medical Center. The medical group on file is Cancer Care of Western Arizona. Dmand AI also links Dr. Lyster to 3 more hospitals, 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lyster practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lyster's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Lyster's licenses on file in 2 states: Arizona and Illinois.

CMS data shows 475 Medicare services from Dr. Lyster across 5 procedure codes in 2024, all of them office visits, for 247 Medicare patients. Medicare paid $33,816 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 247 Medicare patients who saw Dr. Lyster in 2024. The largest group is 65 to 74, with 112 patients. 74% of them have high cholesterol, and 66% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lyster's median patient age at 71, with 52% women.

In 2024, Dr. Lyster wrote 385 Medicare Part D claims for 99 patients. 78% of them were for generic drugs. CMS names the drug for 210 of them, across 12 drugs with 11 or more claims each, at $426,176 in total drug cost. In 2023, CMS named 207 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Lyster for performance year 2024, reported as part of a group. Dr. Lyster accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 294 general payments to Dr. Lyster from 45 drug and device companies from 2016 to 2024. Royalties and licenses make up the largest share, 96% of the total. Medtronic Vascular, Inc. paid the most, $125,205.